Cited by 441Adenosine and Purinergic SignalingImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

Adenosine receptors in regulation of dendritic cell differentiation and function

Open access

Novitskiy, Sergey V., Ryzhov, Sergey, Zaynagetdinov, Rinat, Goldstein, Anna E., Huang, Yuhui, Tikhomirov, Oleg Y., Blackburn, Michael R., Biaggioni, Italo, Carbone, David P., Feoktistov, Igor, Dikov, Mikhail M.·2008·Blood

DOI 10.1182/blood-2008-02-136325PMC PMC2518889

Open this paper in CoChat — free account Open PDF

Abstract

Differentiation of functional dendritic cells (DCs) critically depends on the microenvironment. DCs differentiate in hypoxic tumor sites and inflamed or damaged tissue. Because local concentrations of adenosine reach high physiologically relevant levels in these conditions, we assessed the expression of adenosine receptors and the effect of their activation on differentiation of human monocytes and mouse peritoneal macrophages and hematopoietic progenitor cells (HPCs) into myeloid DCs. Stimulation of adenosine receptors skews DC differentiation toward a distinct cell population characterized by expression of both DC and monocyte/macrophage cell surface markers. Pharmacologic analysis and experiments with cells from A2B adenosine receptor knockout mice identified A2B receptor as the mediator of adenosine effects on DCs. Unlike normal myeloid DCs, adenosine-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune suppressor, and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-β, and IDO. They promoted tumor growth if injected into tumors implanted in mice. Using adenosine desaminase knockout animals, we showed that DCs with proangiogenic phenotype are highly abundant under conditions associated with elevated levels of extracellular adenosine in vivo. Adenosine signaling through A2B receptor is an important factor of aberrant DC differentiation and generation of tolerogenic, angiogenic, and proinflammatory cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2008-02-136325

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Inflammation and cancer
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Springer eBooks · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,962
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Receptors for Purines and Pyrimidines
Ralevic, V., & Burnstock, G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01373-5 · Cited by 2,028
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,095
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900
Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion
Zea, A. H., Rodrı́guez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D. F., Quiceno, D. G., Youmans, A. J., O’Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 852
Adenosine, an endogenous anti-inflammatory agent
Cronstein, B. N. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.76.1.5 · Cited by 633
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells11Abbreviations: cAMP, cyclic adenosine 3′,5′-monophosphate; CHO, Chinese hamster ovary; NBMPR, nitrobenzylthioinosine; and NECA, 5′-N-ethyl carboxamido adenosine.
Fredholm, B. B., Irenius, E., Kull, B., & Schulte, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00570-0 · Cited by 430

Show all 44 references

Research works printed but not linked: 1

Merrill, 1997, Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis., Arthritis Rheum, 40, 1308

Sorted by citations

Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
CD4 T cells: fates, functions, and faults
Zhu, J., & Paul, W. E. (2008) · Blood · doi:10.1182/blood-2008-05-078154 · Cited by 1,915
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.86 · Cited by 867
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Metabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 722
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 621
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Mu, C., Huang, J., Chen, Y., Chen, C., & Zhang, X. (2010) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 590
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N. M., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 570
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 557
Nucleotide metabolism: a pan-cancer metabolic dependency
Mullen, N. J., & Singh, P. K. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00557-7 · Cited by 502
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 502
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Viganó, S., Alatzoglou, D., Irving, M. B., Ménétrier‐Caux, C., Caux, C., Romero, P. J., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 434
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 370
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K. M., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 346
Targeting CD39 in cancer
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 332
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Ohta, A., & Sitkovsky, M. V. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00304 · Cited by 330
Monocytes in the Tumor Microenvironment
Ugel, S., Canè, S., Sanctis, F. D., & Bronte, V. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 327
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 318
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., & Székvölgyi, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00151 · Cited by 319
Purinergic signalling and immune cells
Burnstock, G., & Boeynaems, J. M. (2014) · Purinergic Signalling · doi:10.1007/s11302-014-9427-2 · Cited by 322
Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
Cekic, C., Day, Y., Sağ, D., & Linden, J. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 320
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2008) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 268
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S. V., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
Self-citation
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers
Peña-Romero, A. C., & Orenes‐Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 268
A2B adenosine receptors in immunity and inflammation
Haskó, G., Csóka, B., Németh, Z. H., Vizi, E. S., & Pacher, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.04.001 · Cited by 232
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase–dependent mechanism
Manches, O., Munn, D. H., Fallahi, A., Lifson, J. D., Chaperot, L., Plumas, J., & Bhardwaj, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34823 · Cited by 247
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Leone, R. D., Lo, Y.-C., & Powell, J. D. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.03.008 · Cited by 225
Targeting tumor-associated macrophages for cancer treatment
Li, M., He, L., Zhu, J. K., Zhang, P., & Liang, S. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00823-5 · Cited by 224
Regulation of Macrophage Function by Adenosine
Haskó, G., & Pacher, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.226852 · Cited by 223
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Willingham, S. B., Ho, P. Y., Hotson, A. N., Hill, C. M., Piccione, E. C., Hsieh, J. Y., Liu, L., Buggy, J. J., McCaffery, I., & Miller, R. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0056 · Cited by 225
Tolerogenic Dendritic Cells Generated with Different Immunosuppressive Cytokines Induce Antigen-Specific Anergy and Regulatory Properties in Memory CD4+ T Cells
Aguilar, H. T., Aguilar-Ruíz, S. R., González‐Pérez, G., Munguía-Fuentes, R., Bajaña, S., Meraz‐Ríos, M. A., & Sánchez‐Torres, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902133 · Cited by 220
A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments
Ohta, A., Ohta, A., Madasu, M. M., Kini, R., Subramanian, M., Goel, N., & Sitkovsky, M. V. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901247 · Cited by 214
Metabolic Control of Dendritic Cell Functions: Digesting Information
Wculek, S. K., Khouili, S. C., Priego, E., Heras‐Murillo, I., & Sancho, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00775 · Cited by 218
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Sek, K., Mølck, C., Stewart, G. D., Kats, L. M., Darcy, P. K., & Beavis, P. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123837 · Cited by 206
ENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Regairaz, A., Alberici, G. F., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2012) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 213
Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology
Ernst, P. B., Garrison, J. C., & Thompson, L. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000108 · Cited by 212
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sağ, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
The Roles of CD73 in Cancer
Gao, Z., Dong, K., & Zhang, H. (2014) · BioMed Research International · doi:10.1155/2014/460654 · Cited by 197
Adenosine signaling and the immune system: When a lot could be too much
Antonioli, L., Fornai, M., Blandizzi, C., Pacher, P., & Haskó, G. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.006 · Cited by 207
Exosomes as mediators of immune regulation and immunotherapy in cancer
Kugeratski, F. G., & Kalluri, R. (2020) · FEBS Journal · doi:10.1111/febs.15558 · Cited by 196
Dendritic Cell Metabolism and Function in Tumors
Giovanelli, P., Sandoval, T. A., & Cubillos‐Ruiz, J. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.004 · Cited by 190
Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations
Antonioli, L., Blandizzi, C., Csóka, B., Pacher, P., & Haskó, G. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.10 · Cited by 186
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W., & Wong, C. C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 187
Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
Wu, V. H., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 185
Adenosine and Inflammation: Here, There and Everywhere
Pasquini, S., Contri, C., Borea, P. A., Vincenzi, F., & Varani, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147685 · Cited by 190
Adenosine: An endogenous modulator of innate immune system with therapeutic potential
Kumar, V., & Sharma, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.005 · Cited by 177
Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β
Regateiro, F. S., Howie, D., Nolan, K. F., Agorogiannis, E. I., Greaves, D. R., Cobbold, S. P., & Waldmann, H. (2011) · European Journal of Immunology · doi:10.1002/eji.201141512 · Cited by 174
Tumor-derived factors modulating dendritic cell function
Zong, J., Keskinov, A. A., Shurin, G. V., & Shurin, M. R. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1820-y · Cited by 173
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
Mittal, D., Sinha, D., Barkauskas, D. S., Young, A., Kalimutho, M., Stannard, K. A., Caramia, F., Haibe‐Kains, B., Stagg, J., Khanna, K. K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0544 · Cited by 166
The resurgence of A2B adenosine receptor signaling
Aherne, C. M., Kewley, E. M., & Eltzschig, H. K. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.05.016 · Cited by 162
Blockade of A2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression Mediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 154
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., Vlaeminck, Y. D., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 154
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Kazemi, M. H., Mohseni, S. R., Hojjat‐Farsangi, M., Anvari, E., Ghalamfarsa, G., Mohammadi, H., & Jadidi‐Niaragh, F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25873 · Cited by 149
Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles
Qi, J., Jin, F., You, Y., Du, Y., Liu, D., Xu, X., Wang, J., Zhu, L., Chen, M., Shu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24902-2 · Cited by 148
Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages
Koscsó, B., Csóka, B., Kókai, E., Németh, Z. H., Pacher, P., Virág, L., Leibovich, S. J., & Haskó, G. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113043 · Cited by 151
Cd73: An Emerging Checkpoint for Cancer Immunotherapy
Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y., & Zhang, B. (2019) · Immunotherapy · doi:10.2217/imt-2018-0200 · Cited by 154
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 151
TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
Novitskiy, S. V., Pickup, M. W., Gorska, A. E., Owens, P., Chytil, A., Aakre, M. E., Wu, H., Shyr, Y., & Moses, H. L. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0100 · Cited by 138
Self-citation
The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
Wilson, J. M., Ross, W. G., Agbai, O. N., Frazier, R., Figler, R. A., Rieger, J. M., Linden, J. M., & Ernst, P. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801279 · Cited by 135
Tumor-Derived Adenosine Promotes Macrophage Proliferation in Human Hepatocellular Carcinoma
Wang, J., Wang, Y., Chu, Y., Li, Z., Yu, X., Huang, Z., Xu, J., & Zheng, L. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.021 · Cited by 133
Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer
Jin, F., Qi, J., Liu, D., You, Y., Shu, G., Du, Y., Wang, J., Xu, X., Ying, X., Ji, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.021 · Cited by 132
ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity
Silva-Vilches, C., Ring, S., & Mahnke, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02581 · Cited by 127
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Augustin, R. C., Leone, R. D., Naing, A., Fong, L. H., Bao, R., & Luke, J. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004089 · Cited by 131
Deconstructing Tick Saliva
Oliveira, C. J. F., Sá‐Nunes, A., Francischetti, I. M. B., Carregaro, V., Anatriello, E., Silva, J. S., Santos, I. K. F. D. M., Ribeiro, J. M. C., & Ferreira, B. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.205047 · Cited by 125
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
Kumar, V. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9349-9 · Cited by 131
Links Between Insulin Resistance, Adenosine A2B Receptors, and Inflammatory Markers in Mice and Humans
Figler, R. A., Wang, G., Srinivasan, S., Jung, D. Y., Zhang, Z., Pankow, J. S., Ravid, K., Fredholm, B. B., Hedrick, C. C., Rich, S. S., et al. (2011) · Diabetes · doi:10.2337/db10-1070 · Cited by 120
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Ryzhov, S. V., Pickup, M. W., Chytil, A., Gorska, A. E., Zhang, Q., Owens, P., Feoktistov, I., Moses, H. L., & Novitskiy, S. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400578 · Cited by 123
Self-citation
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 119
Targeting A2 adenosine receptors in cancer
Allard, D., Turcotte, M., & Stagg, J. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.8 · Cited by 120
Orchestration of Angiogenesis by Immune Cells
Bruno, A., Pagani, A., Pulze, L., Albini, A., Dallaglio, K., Noonan, D. M., & Mortara, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00131 · Cited by 117
Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape
Ghiringhelli, F., Bruchard, M., Chalmin, F., & Rébé, C. (2012) · BioMed Research International · doi:10.1155/2012/473712 · Cited by 120
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
Geoghegan, J. C., Diedrich, G., Lu, X., Rosenthal, K., Sachsenmeier, K. F., Wu, H., Dall’Acqua, W. F., & Damschroder, M. M. (2016) · mAbs · doi:10.1080/19420862.2016.1143182 · Cited by 113
Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment
Wang, J., He, Y., Hu, F., Hu, C., Sun, Y., Yang, K., & Yang, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212223 · Cited by 122
Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer
Жулай, Г. А., Олейник, Е. К., Shibaev, M., & Ignatev, K. (2022) · Biomolecules · doi:10.3390/biom12030418 · Cited by 110
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model
Sorrentino, C., Miele, L., Porta, A., Pinto, A., & Morello, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4393 · Cited by 112
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
Borodovsky, A., Barbon, C. M., Wang, Y., Ye, M., Prickett, L. B., Chandra, D., Shaw, J., Deng, N., Sachsenmeier, K. F., Clarke, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000417 · Cited by 108
Adenosine Receptors in Health and Disease
Gessi, S., Merighi, S., Varani, K., & Borea, P. A. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00002-3 · Cited by 103
A2B Adenosine Receptor and Cancer
Gao, Z., & Jacobson, K. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205139 · Cited by 102
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 105
Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
Mello, P. D. A., Coutinho‐Silva, R., & Savio, L. E. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01526 · Cited by 108
Metabolic Stress in the Immune Function of T Cells, Macrophages and Dendritic Cells
Domblides, C., Lartigue, L., & Faustin, B. (2018) · Cells · doi:10.3390/cells7070068 · Cited by 99
The A2B Adenosine Receptor Promotes Th17 Differentiation via Stimulation of Dendritic Cell IL-6
Wilson, J. M., Kurtz, C. C., Black, S. G., Ross, W. G., Alam, M. S., Linden, J. M., & Ernst, P. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100117 · Cited by 97
Purinergic Signaling in the Hallmarks of Cancer
Campos‐Contreras, A. D. R., Díaz‐Muñoz, M., & Vázquez‐Cuevas, F. G. (2020) · Cells · doi:10.3390/cells9071612 · Cited by 103
The yin and yang functions of extracellular ATP and adenosine in tumor immunity
Feng, L., Cai, Y., Zhu, M., Xing, L., & Wang, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01195-x · Cited by 94
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies
Mossenta, M., Busato, D., Bo, M. D., & Toffoli, G. (2020) · Cancers · doi:10.3390/cancers12061668 · Cited by 93
Adenosine A2B Receptor: From Cell Biology to Human Diseases
Sun, Y., & Huang, P. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00037 · Cited by 91
Role of the P2Y12 Receptor in the Modulation of Murine Dendritic Cell Function by ADP
Addi, A. B., Cammarata, D., Conley, P. B., Boeynaems, J., & Robaye, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901799 · Cited by 93
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 88
Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Yu, F., Zhu, C., Xie, Q., & Wang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00237 · Cited by 86
Metabolic Influences That Regulate Dendritic Cell Function in Tumors
Dong, H., & Bullock, T. N. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00024 · Cited by 89

Authors: Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., & Dikov, M. M.
Affiliations: Division of Hematology/Oncology,
Department of Medicine,
Vanderbilt University (US)
Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School
ORCID: Novitskiy, Sergey V.
Ryzhov, Sergey
Zaynagetdinov, Rinat
Huang, Yuhui
Blackburn, Michael R.
Biaggioni, Italo
Carbone, David P.
Feoktistov, Igor
Venue: Blood
Publisher: American Society of Hematology
Published: 2008-09-01
Volume: 112
Issue: 5
Pages: 1822-1831
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2008-02-136325
PMC: PMC2518889
OpenAlex: W1981552113
Cited by: 430
References: 44
Citations by year: 2026: 17 · 2025: 18 · 2024: 28 · 2023: 40 · 2022: 33 · 2021: 33 · 2020: 43 · 2019: 23 · 2018: 24 · 2017: 27 · 2016: 17 · 2015: 13 · 2014: 24 · 2013: 18 · 2012: 18
FWCI: 11.40
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Histiocytosis Association
Vanderbilt University
Vanderbilt-Ingram Cancer Center (5P30-CA068485, CA100562, CA068485)
National Institutes of Health (CA-068485)
National Heart, Lung, and Blood Institute (R01HL070952, HL70952, R01HL076306, R01HL070073, HL76306)
National Cancer Institute (R01CA100562, CA76321, R01CA076321, CA100562, P30CA068485)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: adenosine receptors, adenosine A2B receptor, dendritic cell differentiation, myeloid dendritic cells, adenosine signaling, monocytes, peritoneal macrophages, hematopoietic progenitor cells, tumor microenvironment, hypoxia, allostimulatory activity, angiogenic factors, immunosuppression, tumor growth, vascular endothelial growth factor, IDO, TGF-beta
MeSH terms: Adenosine, Adenosine Deaminase, Animals, Base Sequence, Cell Differentiation, Dendritic Cells, Humans, Immune Tolerance, Male, Mice, Inbred C57BL, Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, DNA Primers, Receptors, Purinergic P1, Mice, Knockout, Inflammation Mediators, Receptor, Adenosine A2B, Mice, Purinergic P1 Receptor Antagonists, Adenosine A2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adenosine receptors in regulation of dendritic cell differentiation and function

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks